Mediar Therapeutics
Clinical trials sponsored by Mediar Therapeutics, explained in plain language.
-
New drug trial targets hardened skin in rare autoimmune disease
Disease control Not yet recruitingThis study is testing an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and hardening. About 85 participants will be randomly assigned to receive either the drug or a placebo via an I…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New kidney disease drug enters first human testing phase
Knowledge-focused Not yet recruitingThis is the first study in humans to test the safety of an experimental drug called MTX-439. Researchers will give the drug to 88 healthy adults and adults with diabetic kidney disease to see how their bodies handle it and check for side effects. The main goal is to find a safe d…
Phase: PHASE1 • Sponsor: Mediar Therapeutics • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:18 UTC